References
- McIntyre RS, Rosenblat JD, and Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399.
- Alnefeesi Y, Tamura JK, Lui LMW, et al. Trace amine-associated receptor 1 (TAAR1): potential application in mood disorders: a systematic review. Neurosci Biobehav Rev. 2021 Dec 1;131:192–210.
- Ling S, Ceban F, Lui LMW, et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022 Jan;36(1):17–30.
- Gill H, Gill B, and Chen-Li D, et al. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2022 Dec;20(12):1263–1273.
- Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019 Sep 5;381(10):903–911.
- Savitz A, Wajs E, Zhang Y, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol. 2021 Dec 8;24(12):965–976.
- Majeed A, Xiong J, Teopiz KM, et al. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs. 2021 Mar;26(1):63–74.
- Fava M, Mazzone E, Freeman M, et al. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 Feb;32(4):18–26.